0
Skip to Content
CureSHANK
Phelan-McDermid Syndrome
For Academia & Industry
Learn about our Initiatives
Our Research Grants
PMS Conceptual Model
EL-PFDD Meeting
CureSHANK Consortium
Funding Opportunities
Research Resources
Landscape Analysis for Industry
Participate in Research
Support Our Work
Our Fundraisers
Take Action
Fundraise Online
Plan an Event
2024 Raise for Reserach
Media
Real Family Stories
Webinars
PMSAD
News
About Us
Board of Directors
Strategic & Scientific Advisors
Our Partners
Financials
Contact Us
Meet Our Team
Donate
CureSHANK
Phelan-McDermid Syndrome
For Academia & Industry
Learn about our Initiatives
Our Research Grants
PMS Conceptual Model
EL-PFDD Meeting
CureSHANK Consortium
Funding Opportunities
Research Resources
Landscape Analysis for Industry
Participate in Research
Support Our Work
Our Fundraisers
Take Action
Fundraise Online
Plan an Event
2024 Raise for Reserach
Media
Real Family Stories
Webinars
PMSAD
News
About Us
Board of Directors
Strategic & Scientific Advisors
Our Partners
Financials
Contact Us
Meet Our Team
Donate
Phelan-McDermid Syndrome
Folder: For Academia & Industry
Back
Learn about our Initiatives
Our Research Grants
PMS Conceptual Model
EL-PFDD Meeting
CureSHANK Consortium
Funding Opportunities
Research Resources
Landscape Analysis for Industry
Participate in Research
Folder: Support Our Work
Back
Our Fundraisers
Take Action
Fundraise Online
Plan an Event
2024 Raise for Reserach
Folder: Media
Back
Real Family Stories
Webinars
PMSAD
News
Folder: About Us
Back
Board of Directors
Strategic & Scientific Advisors
Our Partners
Financials
Contact Us
Meet Our Team
Donate

News & Updates

Categories
  • Awareness 5
  • CLINICAL TRIALS 1
  • Funding 2
  • Learn More 5
  • Newsletters 1
  • Updates 6
Jaguar Announces FDA Approval to Begin Phase 1 Clinical Trials for Phelan-McDermid Syndrome
Updates Abby Lievense 1/31/24 Updates Abby Lievense 1/31/24

Jaguar Announces FDA Approval to Begin Phase 1 Clinical Trials for Phelan-McDermid Syndrome

It is a very exciting day for the PMS community: FDA has cleared Jaguar's JAG201 for Phase 1 clinical trials! JAG201 is a gene therapy addressing SHANK3 deletions and variants, which cause Phelan-McDermid syndrome.

Read More
CureSHANK founder Named Rising Star
Updates CureSHANK 7/13/22 Updates CureSHANK 7/13/22

CureSHANK founder Named Rising Star

Abby Lievense inspires with her story of resilience and dedication to her son, Darus.

Read More
Breaking News
Updates CureSHANK 12/15/21 Updates CureSHANK 12/15/21

Breaking News

We are excited to share the announcement of our first gene-based therapeutic program for Phelan-McDermid syndrome!

Read More
CureSHANK is part of COMBINEDbrain ensuring more SHANK3 visibility
Updates Abby Lievense 4/21/21 Updates Abby Lievense 4/21/21

CureSHANK is part of COMBINEDbrain ensuring more SHANK3 visibility

CureSHANK is a proud member of COMBINEDbrain a non-profit consortium of 25 patient-advocacy groups, each representing a different rare genetic neurodevelopmental disorder.

Read More
Happy Birthday Daria!
Updates Paulina Rychenkova 2/23/21 Updates Paulina Rychenkova 2/23/21

Happy Birthday Daria!

Daria - the daughter of CureSHANK’s co-founder Paulina Rychenkova, - is officially a teenager today!

Read More
CureSHANK Strategic Programs
Updates Abby Lievense 12/29/20 Updates Abby Lievense 12/29/20

CureSHANK Strategic Programs

We’re excited to announce the launch of CureSHANK’s two signature programs to address the major gap areas in drug development for Phelan-McDermid Syndrome:

Read More

CureSHANK has a singular purpose: To accelerate the development of treatments for Phelan-McDermid syndrome & SHANK-related disorders.

Subscribe to our email list

Learn More

Phelan-McDermid Syndrome
For Academia & Industry
Participate in Research
Real Family Stories
Webinars
News

Support

Take Action
Fundraise Online
Plan an Event
Purchase Merchandise

Donate now

About us

Homepage
Board of Directors
Strategic Advisors
Our Partners
Financials
Contact Us


© 2024 CureSHANK | CureSHANK is a California-based Nonprofit Public Benefit Corporation with 501c3 approval from IRS.